Quantcast

Latest Dendreon Stories

2011-06-29 19:04:00

SEATTLE, June 29, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE(®) (sipuleucel-T) across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The Los...

2011-06-16 05:00:00

SEATTLE, June 16, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the NASDAQ OMX 26th Investor Program in London on June 21, 2011 at 9:30 a.m. GMT (4:30 a.m. ET). The presentation will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations...

2011-06-13 17:32:00

SEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year(®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr. Gold has served as CEO of Dendreon since 2003, and under his leadership the company last year received U.S. Food and Drug Administration approval for PROVENGE®...

2011-06-08 08:00:00

VANCOUVER, British Columbia, June 8, 2011 /PRNewswire-Asia/ -- Insiderslab.com caught up the convincing insiders trading today for the following companies: QUALCOMM, OpenTable, Automatic Data Processing, Windstream, Citrix, & Dendreon. No needs to attend the board minutes, individual investors now have a chance to trade even better than those insiders. Insider's buy and sell is a valuable screen to help investors determine which stocks to track further. Academic evidence indicates...

2011-06-03 12:24:15

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4. (ABSTRACT #4534) In an exploratory, multi-institutional analysis, researchers administered the vaccine APC8015F to a group of patients...

2011-05-27 08:30:00

VANCOUVER, British Columbia, May 27, 2011 /PRNewswire-Asia/ -- Insiderslab.com filtered out all but the most substantial insider transactions made by insiders. Teradyne, Terex, Dendreon, Activision, Aruba, & Momenta are the companies in focus today. More and more investors using the trend following trading strategies are looking for the signal hidden in the insider trading. When corporate insiders in one industry or sector as a whole are buying or selling their stocks simultaneously,...

2011-05-20 05:00:00

SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m. ET Goldman Sachs Annual Global Healthcare Conference in Rancho Palos Verdes, CA on June 7, 2011 at 2:00 p.m. PT The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen...

2011-05-19 07:15:00

AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak(TM), its lead agent for patients with newly diagnosed prostate cancer. The trial is expected to accrue 711 patients starting mid-2011 with definitive results expected by 2015. The randomized study will...

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGE® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois. "Time to Disease-Related Pain After Sipuleucel-T in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Results from 3 Randomized Phase 3 Trials," abstract #4661. McCormick Place Hall A (Poster...

2011-05-18 17:00:00

SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGE® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois. The three abstracts will be presented on Monday, June 6, 2011, from 8:00 a.m. to 12:00 p.m. CT in the McCormick Place Hall A at the...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related